Orchard grows team with commercial and legal leaders

21 March 2018

A couple of additions have been made to the executive team of Orchard Therapeutics, a privately-held clinical-stage biotech based in the UK and USA.

Orchard, which specializes in developing gene therapies for rare disorders, has named Jason Meyenburg as chief commercial officer and John Ilett as general counsel and company secretary.

Mr Meyenburg held the same role at US biopharma company Sucampo Pharmaceuticals (Nasdaq: SCMP) and the rare disease specialist that it acquired, Vtesse. He also led commercial operations at Alexion Pharmaceuticals (Nasdaq: ALXN) in the USA and Latin America in the hematology, nephrology and metabolic business units, and held commercial leadership roles expanding access to the firm's products in Europe, the Middle-East, Africa and Japan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK